Search PubMed⌕ Search

Biomedical subjects

Y Negishi

Publications and source records attributed to Y Negishi.

53 records · Page 3Linked to original sources
PubMed1986

Studies of natural killer activity and augmentation by OK-432 in patients with gynecological malignancies.

The natural killer (NK) and antibody-dependent cellular cytotoxic (ADCC) activities were determined in peripheral blood lymphocytes of patients with gynecologic malignancy. The effects of a preparation of Streptococcus pyogenes (OK-432) and of interferon were determined. Patients with advanced cancer exhibited lower natural cytotoxicity than normal women. NK and ADCC activities were decreased following surgery and NK activity was decreased following chemotherapy. Radiation reduced the percentage of Leu-7-positive cells in the circulation of the patients. OK-432 augmented the NK activity of both healthy women and patients with early malignancy. Interferon was less effective than OK-432 in augmenting NK activity.

Adult↗
PubMed1985

[Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].

CA 125, CA 19-9, TPA and IAP were useful for diagnosis of ovarian cancer. CA 125 was localized immunohistochemically in the surface and cytoplasma of cancer cells of serous cystadenocarcinomas, clear cell carcinomas, endometrioid carcinomas and undifferentiated carcinomas and CA 19-9 localized in mucinous cystadenocarcinomas and endometrioid carcinomas. When the cut off value of CA 125 was set by 35 U/ml in the control group, the patients with serous cystadenocarcinoma showed positive in 81%, resulting by 1,766.5 U/ml as an average value. As for CA 19-9 having set by 37 U/ml as the cut off value, patients suffering from mucinous cystadenocarcinoma who revealed positive by 60%, were 194 U/ml in an average value. It is considered that measuring values of CA 125 and CA 19-9 are valuable not only to diagnose as ovarian cancers but also to evaluate their prognosis.

Adenocarcinoma, Mucinous↗
PubMed1984

[A study on tumor marker of tissue-polypeptide-antigen (TPA) in gynecologic malignancies].

Tissue polypeptide-antigen (TPA), a tumor-associated antigen reported by Bjorklund et al., is a single chain polypeptide of approximately 22,000-45,000 molecular weight, which is being studied in various fields as a tumor marker. We determined the serum TPA level and tissue distribution of TPA in patients with gynecologic malignancies and healthy women. In healthy women, the serum TPA level was under 110 mu/l, without any relation to age or sex. In benign tumors, the mean serum TPA was 123.9 mu/l and it is comparable with that in healthy women. In cervical cancers, it was 212 mu/l and significantly higher than those in healthy women and in patients with benign tumors (p less than 0.01). In ovarian cancers, it was 414.7 mu/l, which showed significantly higher levels of serum TPA in ovarian cancers than those in healthy women and in patients with benign tumor, and it was also significantly higher than that in cervical cancers (p less than 0.001). As for the values after treatment, the serum TPA level clearly tended to fall in patients exhibiting good response, and tended to rise in those showing poor response. TPA was markedly localized in the cancer cells, but was almost entirely absent from the normal tissues of the cervix and endometrium.

Adenocarcinoma, Mucinous↗
PubMed1984

Tumor associated antigen in ovarian carcinoma.

Tumor associated antigen present in the cyst fluid of a patient with papillary mucinous cytadenocarcinoma of the ovary was prepared by ammonium sulfate precipitation. The dialyzed precipitate was emulsified in complete Freund's adjuvant and injected into rabbits followed by booster doses of the antigen in saline. The resulting antiserum was absorbed with normal human serum and normal liver and AB type blood cells. The absorbed antiserum was found to react with mucinous cyst adenocarcinoma, borderline mucinous cystadenoma and gastric and rectal cancers by immunofluoresence and immunoperoxidase. No reactivity was noted by the same methods in serous-cystadenocarcinoma and mesonephroid tumors. The molecular weight of the tumor associated antigen in cyst fluid of a patient with mucinous cystadenocarcinoma was determined by Enzyme immunoassay and Gel filtration to be 450,000 daltons.

Antigens, Neoplasm↗
PubMed1984

Type II pneumocytes in pulmonary tumors. Implications for histogenesis.

Bronchioloalveolar carcinomas (n = 45), intravascular bronchiolo-alveolar tumors (n = 8), and sclerosing hemangiomas of the lung (n = 2) were stained for surfactant apoprotein by the immunoperoxidase method. Of the bronchiolo-alveolar carcinomas, 12 were found to be carcinomas of type II pneumocytes and the remaining 33 tumors were designated as nontype II pneumocytic bronchiolo-alveolar carcinomas. Twenty-five of these tumors displayed trapped benign type II pneumocytes within the tumor masses. In the case of intravascular bronchioloalveolar tumors, none of the tumors demonstrated staining of tumor cells for surfactant apoprotein. In the two cases of sclerosing hemangiomas, the type II pneumocytes were exuberant and numerous, and in one case contained intranuclear inclusions of surfactant apoprotein. This article discusses the implication of the presence of benign type II pneumocytes in pulmonary tumors.

Adenocarcinoma, Bronchiolo-Alveolar↗
PubMed1983

Psychotherapeutic study of tics in childhood--on relationship between family dynamics and onset.

Among the tic children who received psychotherapy, 29 cases, which were followed up for more than five years (mean, 8 years) since the onset was available, were selected. Tics were classified as follows based on the process of psychotherapy; monosymptomatic process group 9, neurotic process group 17, distortion of personality development process group 3. The neurotic process group indicated the best prognosis. Next was the monosymptomatic process group. The distortion of personality development process group presented the least favorable prognosis. From the result of psychotherapy, the following methods appeared to be effective, for each of the groups above. "Activity therapy" for the monosymptomatic process group; "intensive therapy" for the neurotic process group: "milieu therapy" for the distortion of personality development group.

Adolescent↗